The Governors of the University of Calgary

Brain Cancer Canada has awarded $68,000 to researchers at the University of Calgary and Alberta Children's Hospital for a clinical trial of a neoantigen-based anti-cancer vaccine targeting DIPG, the most aggressive form of pediatric brain cancer.

A new study published in Annals of Internal Medicine found that the seated saline suppression test (SSST) commonly used to confirm primary aldosteronism is often inaccurate and may prevent patients from receiving effective treatment.

Two major clinical trials demonstrate that hybrid closed-loop insulin delivery systems significantly improve time in range and reduce hypoglycemia in pregnant women with type 1 diabetes compared to standard care.

The FDA has approved Genentech's TNKase, a clot-dissolving agent, for treating acute ischemic stroke in adults, marking the company's second stroke treatment approval.

A large Canadian retrospective study of 32,667 preterm infants reveals probiotics significantly reduced mortality rates, with an adjusted odds ratio of 0.62 in infants born before 34 weeks gestation.

Late-breaking ESCAPE-MeVO trial results reveal endovascular thrombectomy combined with best medical care offers no additional benefit over best medical care alone for medium-vessel occlusion stroke patients.

• University of Calgary researchers are initiating a validation study for the Mira Hormone Monitor, a device claiming to provide precise numerical readings of hormone biomarkers from urine samples. • The study, requiring Health Canada clearance, aims to validate the device's claimed 99% lab-grade accuracy using ultrasound testing as the gold standard for comparison. • The technology could revolutionize women's healthcare by enabling daily hormone tracking for conditions like PCOS and PMS, while providing comprehensive data for healthcare providers.

A clinical trial at the University of Calgary is testing probenecid, a gout medication, to alleviate opioid withdrawal symptoms.

A clinical trial found that ustekinumab, a drug currently used for psoriasis, preserved insulin production in young type 1 diabetes patients, with C-peptide levels 49% higher after one year compared to placebo.

Elranatamab demonstrated a 61% objective response rate in patients with penta- or triple-class refractory multiple myeloma who had not received prior BCMA-targeted therapy.